Postmenopausal Hormone Therapy: Does It Have a Role in Cardiovascular Prevention Today?
Cardiovascular disease is the leading cause of mortality in women. Results from observational studies consistently demonstrated lower heart disease rates among women who used hormone replacement therapy (HRT) compared to non-users. Data from two large randomized controlled trials showed mixed results. Subsequent post-hoc analysis found cardiovascular disease among HRT users to be lower than non-users in women 50 to 59 years of age or less than 10 years post-menopause. This has sparked much debate on the role of postmenopausal hormone therapy, especially in peri-menopausal women. Two hypotheses have been suggested to explain this divergent data: 1) HRT may be cardioprotective when introduced prior to atherosclerosis development but may be harmful in women with established CVD; or 2) HRT may be useful when started closer to menopause initiation and harmful when started later in life.
KeywordsHormone replacement therapy Cardiovascular disease Coronary artery disease Stroke Menopause Coronary artery calcium
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.National Vital Statistics Reports. Volume 58, Number 19 May 20, 2010 http://www.cdc.gov/NCHS/data/nvsr/nvsr58/nvsr58_19.pdf.
- 2.Global atlas on cardiovascular disease prevention and control. http://whqlibdoc.who.int/publications/2011/9789241564373_eng.pdf.
- 3.Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association. http://circ.ahajournals.org/content/early/2011/12/15/CIR.0b013e31823ac046.citation.
- 6.• Aging, menopause, cardiovascular disease and HRT. International Menopause Society Consensus Statement. Climacteric 2009;12:368–77. This paper is a consensus statement on cardiovascular aspects on menopause and available treatments written by international experts. Google Scholar
- 9.• Estrogen and progesterone use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:242–55. This position statement aims to clarify the risks and benefits of hormone replacement therapy for prevention and treatment of menopause-related symptoms. Google Scholar
- 11.Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Journal of American Medical Association 1995 Jan 18;273:199–208.Google Scholar
- 21.Clarkson TB. Progestogens and cardiovascular disease. A critical review. Journal of Reproductive Medicine. 1999;44:180–4.Google Scholar
- 26.Rosenfeld ME, Kauser K, Martin-McNulty B. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis. 2002;164:251–9.PubMedCrossRefGoogle Scholar
- 27.Hu P, Greendale GA, Palla SL, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix mettaloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. 2006;185:347–52.PubMedCrossRefGoogle Scholar
- 33.• Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of American College of Cardiology 2010;56:e50–103. This guideline published by the American College of Cardiology shows how to risk stratify patients with no known CAD. Google Scholar
- 35.ELITE: Early versus Late Intervention Trial with Estradiol. Bethesda, MD: National Institute of Aging, 2007. http://clinicaltrials.gov/ct2/show/NCT00114517.